LianBio (NASDAQ:LIAN) Shares Down 5.3%

LianBio (NASDAQ:LIAN) dropped 5.3% during mid-day trading on Friday . The stock traded as low as $4.84 and last traded at $4.84. Approximately 6 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 148,715 shares. The stock had previously closed at $5.11.

LIAN has been the topic of several research reports. Jefferies Financial Group started coverage on LianBio in a research report on Friday, November 26th. They issued a “buy” rating and a $24.00 target price on the stock. Bank of America initiated coverage on shares of LianBio in a research note on Friday, November 26th. They set a “buy” rating on the stock. Raymond James started coverage on shares of LianBio in a research report on Wednesday, November 24th. They set an “outperform” rating and a $27.00 price target for the company. Finally, The Goldman Sachs Group started coverage on shares of LianBio in a report on Friday, November 26th. They issued a “neutral” rating and a $18.58 price objective for the company.

The firm has a 50-day simple moving average of $9.16.

LianBio (NASDAQ:LIAN) last posted its quarterly earnings data on Wednesday, December 8th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.06). As a group, sell-side analysts anticipate that LianBio will post -4.51 EPS for the current fiscal year.

LianBio Company Profile (NASDAQ:LIAN)

LianBio is a cross-border biotechnology company dedicated to bringing medicines to patients principally in China and other major Asian markets. LianBio is based in SHANGHAI, China.

Further Reading: P/E Growth (PEG)

Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.